BioSpace News Archive

Drug Development

Karolinska Development’s portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents

Karolinska Development’s portfolio company Aprea presents results from studies with APR-246 in combination with immune checkpoint blockade.

April 3, 2019
·
2 min read
Tipping the scales: Labeling proteins with ubiquitin paves new road to cell regulation research

Human cells have a sophisticated regulatory system at their disposal: labeling proteins with the small molecule ubiquitin.

April 3, 2019
·
4 min read
Business

Sangamo Jumps 28 Percent on Positive Early Hemophilia Trial Data

The California-based company also shared positive early data from a beta thalassemia study and announced plans to increase AAV manufacturing.

April 3, 2019
·
3 min read
·
Alex Keown
Career Advice

The Top 4 Unique Benefits of Life Sciences Companies - Are You Getting Them?

Have you thought about what benefits are important to you? Would you request certain benefits from your current employer, or during an interview for a new job?

April 3, 2019
·
3 min read
·
Porschia Parker
Business

Dyne Therapeutics Launches With $50 Million Series A to Treat Muscle Diseases

Dyne Therapeutics closed on a $50 million Series A round. The company was founded, seeded and incubated by Atlas Venture, who led the round, which was joined by Forbion and MPM Capital.

April 3, 2019
·
3 min read
·
Mark Terry
Business

Editas and BlueRock Forge Agreement to Develop Novel Engineered Cell Medicines

Cambridge, Mass.-based Editas Medicine and privately-held BlueRock Therapeutics have teamed up and combined their genome editing and cell therapy technologies to discover, develop and manufacture novel engineered cell medicines.

April 3, 2019
·
2 min read
·
Alex Keown
Business

ESTEVE Appoints Thomas B. Riisager as Chief Corporate Strategy & Business Development Officer

ESTEVE has announced the appointment of Thomas B Riisager as Chief Corporate Strategy & Business Development Officer, to be heading Corporate Strategy & Business Development for the pharmaceutical group.

April 3, 2019
·
2 min read
Deals

AgomAb Therapeutics Completes Euros 21m Series A Financing

EUR 21m Series A secured with international investor syndicate co-led by V-Bio Ventures (Belgium) and Advent France Biotechnology (France), and joined by Boehringer Ingelheim Venture Fund (Germany), Omnes (France) and Pontifax (Israel)

April 3, 2019
·
5 min read
Business

dentalcorp announces appointment of Robert Masson as Chief Financial Officer

dentalcorp, Canada’s leading network of dental practices, announced the appointment of Robert Masson as Chief Financial Officer, effective May 8.

April 3, 2019
·
1 min read
Invitation to Essity’s Q1 2019 Press Conference

The interim report will be published on April 25, 2019 at approximately 07:00 CET. The subsequent press conference will be held at 09:00 CET at Essity’s headquarters, Waterfront Building, Klarabergsviadukten 63, Stockholm, Sweden.

April 3, 2019
·
1 min read